# Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

> **NCT02396134** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 61 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- Adult Hodgkin Lymphoma
- Adult Non-Hodgkin Lymphoma
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Cytomegaloviral Infection
- Hematopoietic and Lymphoid Cell Neoplasm
- HLA-A*0201 Positive Cells Present
- Myelodysplastic Syndrome
- Adult Lymphoblastic Lymphoma
- Chronic Lymphocytic Leukemia
- Myelofibrosis
- Myeloproliferative Neoplasm

## Interventions

- **BIOLOGICAL:** CMVpp65-A*0201 peptide vaccine
- **OTHER:** Placebo
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02396134
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2018-03-04
- **Final completion:** 2024-09-19
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396134, "Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02396134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*